Pensionfund Sabic Purchases New Position in Merck & Co., Inc. $MRK

Pensionfund Sabic purchased a new stake in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, Holdings Channel.com reports. The firm purchased 29,000 shares of the company’s stock, valued at approximately $3,053,000.

Several other hedge funds have also modified their holdings of MRK. Darwin Wealth Management LLC boosted its position in shares of Merck & Co., Inc. by 237.4% during the 3rd quarter. Darwin Wealth Management LLC now owns 307 shares of the company’s stock valued at $26,000 after acquiring an additional 216 shares during the last quarter. Kilter Group LLC bought a new stake in Merck & Co., Inc. in the second quarter worth $27,000. Bare Financial Services Inc raised its stake in Merck & Co., Inc. by 51.9% during the second quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after purchasing an additional 125 shares in the last quarter. Barnes Dennig Private Wealth Management LLC raised its stake in Merck & Co., Inc. by 302.3% during the third quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company’s stock valued at $30,000 after purchasing an additional 266 shares in the last quarter. Finally, Evolution Wealth Management Inc. bought a new position in Merck & Co., Inc. during the second quarter valued at $31,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Signed a multi‑year research collaboration with Quotient Therapeutics to discover IBD drug targets using Quotient’s somatic genomics platform; the deal includes an upfront payment and a milestone structure worth up to $2.2 billion, giving Merck access to novel target‑finding technology that could expand its inflammation franchise and long‑term growth prospects. Quotient Therapeutics Announces Collaboration with Merck to Discover Novel Drug Targets in Inflammatory Bowel Disease Using Somatic Genomics Platform Technology
• Positive Sentiment: Analyst/press writeups note the strategic value of the Quotient tie‑up and discuss valuation upside if the somatic‑genomics approach yields actionable targets—this coverage can help re‑rate MRK on pipeline optionality and future royalties/booked milestones. Assessing Merck (MRK) Valuation After New IBD Genetics Collaboration With Quotient Therapeutics
• Positive Sentiment: Commercial progress for WINREVAIR® (sotatercept): several Canadian jurisdictions have added the product to public formularies following a pCPA agreement, improving access and supporting upside in pulmonary arterial hypertension revenue. Greater public coverage reduces uptake risk and supports revenue visibility in Canada. New Public Listings for Canadians Living with Pulmonary Arterial Hypertension
• Positive Sentiment: Merck’s most recent quarterly results (reported Feb 3) beat EPS and revenue estimates and management provided FY2026 EPS guidance—this fundamental backdrop (solid margins, strong ROE, and guidance) underpins investor confidence alongside the new deals. (Company filings and earnings release)
• Neutral Sentiment: Market commentary and scans flagged MRK among S&P 500 large caps to watch and noted recent outperformance versus the index—these are market‑flow and sentiment items that can amplify moves but don’t change fundamentals by themselves. 1 S&P 500 Stock to Target This Week and 2 We Ignore
• Neutral Sentiment: Price recaps and short pieces (Zacks/Yahoo) note recent gains—useful for tracking momentum but not new catalysts. Merck (MRK) Exceeds Market Returns: Some Facts to Consider

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $116.26 on Wednesday. The company has a market capitalization of $287.43 billion, a price-to-earnings ratio of 15.97, a PEG ratio of 2.24 and a beta of 0.27. Merck & Co., Inc. has a 12 month low of $73.31 and a 12 month high of $125.14. The firm’s 50-day moving average is $116.10 and its 200 day moving average is $101.32. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The company had revenue of $16.40 billion for the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Research analysts predict that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a $0.85 dividend. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRK. BMO Capital Markets raised shares of Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. The Goldman Sachs Group increased their price target on shares of Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Deutsche Bank Aktiengesellschaft upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Friday, February 13th. Finally, Bank of America boosted their price objective on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average price target of $127.13.

Insider Activity

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $118.41, for a total value of $1,184,100.00. Following the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. This represents a 12.40% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 121,573 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $119.15, for a total value of $14,485,422.95. Following the completion of the sale, the executive vice president owned 68,916 shares in the company, valued at approximately $8,211,341.40. The trade was a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 320,176 shares of company stock worth $38,281,735 in the last three months. Corporate insiders own 0.09% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.